A new investigational drug is known as iniparib promising for a type of breast cancer called "triple negative" breast cancer, which are known to be difficult to treat in advanced stages is known. The research is published in the latest issue of the New England Journal of Medicine. Here is some information on triple negative breast cancer: • In this cancer, the cells do not contain receptors for estrogen, progesterone, or does human epidermal growth factor type 2 (HER2) • This, thatCancer is not the growth fueled by estrogen, progesterone, or growth signals from the HER2 protein so hormonal therapies and therapies • HER2, both pillars of treatment are not likely to be effective, it accounts for 10 to 20% of all breast cancer Researchers at the Baylor Charles A. Sammons Cancer Center in Dallas was more than 100 patients with advanced triple-negative breast cancer, standard chemotherapy treatment, consisting gemcitanbine from the drugs and carboplatin. InIn addition, half of the patients received the investigational iniparib. More than half of those who received iniparib as clinically benefited from treatment, compared with only about a third of those who received chemotherapy without iniparib. In addition iniparib therapy with a higher tumor response to treatment and a longer duration of time was connected before the disease began to progress. Both treatment regimens were well tolerated about the same.Today ...
http://www.youtube.com/watch?v=4MdnAKbEJ60&hl=en
Friends Link : Swine Flu Vaccine
0 comments:
Post a Comment